C4 Therapeutics(C4 Therapeutics, Inc.)第二季度财报显示,公司每股亏损为0.18美元,较IBES预估的每股亏损0.23美元表现更佳。与此同时,公司第二季度营收达到660万美元,超越市场预期的400万美元。
C4 Therapeutics(C4 Therapeutics, Inc.)第二季度财报显示,公司每股亏损为0.18美元,较IBES预估的每股亏损0.23美元表现更佳。与此同时,公司第二季度营收达到660万美元,超越市场预期的400万美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.